WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
Dieses mit IHMC CmapTools erstellte CMap hat Informationen bezüglich: GBS Treatment, Anti-Ganglioside Antibodies IvIg Therapy after 2 weeks, Anti-Ganglioside Antibodies Combined Treatment PE as Primary, Anti-Ganglioside Antibodies No Treatment Damage to Peripheral Nervous System: Gangliosides Later: Damage to Myelin (Acute and Chronic Phase) Recuperation possible, Comorbidities ? Relapse more likely, Comorbidities ???? Relapses more likely (Formation of Memory Cells) Treatment less effective, Anti-Ganglioside Antibodies Combined Treatment No significant improvements to Single Treatment, Anti-Ganglioside Antibodies IvIg Therapy Destruction of Self Antibodies Inhibition of Complex Activation by Self Antibodies Complex Activation of Destruction of Self Antibodies, PE as Primary ???? Relapse more likely, Anti-Ganglioside Antibodies Plasma Exchange Therapy (PE) Removal of Plasma with Antibodies, Exchange for foreign Plasma, Comorbidities ???? Relapse less likely, Anti-Ganglioside Antibodies Combined Treatment IvIg as Primary, Comorbidities Chances Of Relapse Increase, Efficiency Decreases, IvIg as Primary ???? Relapse less likely, after 2 weeks After 2 Weeks Chances Of Relapse Increase, Efficiency Decreases, Anti-Ganglioside Antibodies Plasma Exchange Therapy (PE) Relapses more likely (Formation of Memory Cells) Treatment less effective